清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

医学 特应性皮炎 禁忌症 安慰剂 人口 随机对照试验 临床试验 内科学 Janus激酶抑制剂 皮肤病科 儿科 贾纳斯激酶 替代医学 环境卫生 病理 细胞因子
作者
Melinda Gooderham,Seth B. Forman,Robert Bissonnette,JEAN SACCUZZO BEEBE,Weidong Zhang,Chris Banfield,Linda Zhu,Jocelyne Papacharalambous,Michael S. Vincent,Elena Peeva
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:155 (12): 1371-1371 被引量:247
标识
DOI:10.1001/jamadermatol.2019.2855
摘要

Importance: Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic dermatitis are inadequate or contraindicated for some patients. Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of atopic dermatitis. Objective: To investigate the efficacy and safety of abrocitinib for patients with moderate to severe atopic dermatitis. Design, Setting, and Participants: A phase 2b, randomized, double-blinded, placebo-controlled, parallel-group trial was conducted from April 15, 2016, to April 4, 2017, at 58 centers in Australia, Canada, Germany, Hungary, and the United States among 267 patients 18 to 75 years of age with a clinical diagnosis of moderate to severe atopic dermatitis for 1 year or more and inadequate response or contraindication to topical medications for 4 weeks or more within 12 months. Efficacy was assessed in the full analysis set, which was a modified intention-to-treat population that included all patients who received 1 dose or more of the study drug except for 4 patients from 1 site. Interventions: Participants were randomly assigned 1:1:1:1:1 to receive abrocitinib (200 mg, 100 mg, 30 mg, or 10 mg) or placebo once daily for 12 weeks. Main Outcomes and Measures: The primary outcome was the proportion of patients achieving an Investigator's Global Assessment of clear (0) or almost clear (1) with an improvement from baseline of 2 grades or more at week 12. The secondary outcome was the percentage change from baseline in the Eczema Area and Severity Index at week 12. Results: Of the 267 participants, 144 were women (mean [SD] age, 40.8 [16.1] years). At week 12, 21 of 48 patients receiving 200 mg of abrocitinib (43.8%; P < .001, 2-sided), 16 of 54 patients receiving 100 mg of abrocitinib (29.6%; P < .001), and 3 of 52 patients receiving placebo (5.8%) achieved grades of clear or almost clear on the Investigator's Global Assessment scale with improvement of 2 grades or more; these rates correspond to maximum effect model-based estimates of 44.5% (95% CI, 26.7%-62.3%) for those receiving 200 mg of abrocitinib, 27.8% (95% CI, 14.8%-40.9%) for those receiving 100 mg of abrocitinib, and 6.3% (95% CI, -0.2% to 12.9%) for those receiving placebo. Reductions in the Eczema Area and Severity Index were 82.6% (90% CI, 72.4%-92.8%; P < .001) for those receiving 200 mg of abrocitinib, 59.0% (90% CI, 48.8%-69.3%; P = .009) for those receiving 100 mg of abrocitinib, and 35.2% (90% CI, 24.4%-46.1%) for those receiving placebo. Adverse events were observed in 184 of 267 patients (68.9%); the most frequently reported adverse events (in ≥3 patients in any group) were dermatitis atopic, upper respiratory tract infection, headache, nausea, and diarrhea. Dose-dependent decreases in platelet count were observed but trended upward toward baseline levels after week 4. Conclusions and Relevance: Once-daily oral abrocitinib was effective and well tolerated for short-term use in adults with moderate to severe atopic dermatitis. Additional trials are necessary to evaluate long-term efficacy and safety. Trial Registration: ClinicalTrials.gov identifier: NCT02780167.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer的应助被王磊磊0811采纳,获得10
2秒前
快乐的雁露完成签到,获得积分10
9秒前
打打的应助被科研通管家采纳,获得10
13秒前
13秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
13秒前
犹豫静白完成签到,获得积分10
23秒前
超级的迎梅完成签到,获得积分10
28秒前
Sunny完成签到,获得积分10
29秒前
儒雅的半青完成签到,获得积分10
31秒前
43秒前
51秒前
光亮的成败完成签到,获得积分10
59秒前
烂漫的诗蕊完成签到,获得积分10
1分钟前
笨笨的夏柳完成签到,获得积分10
1分钟前
平常觅风完成签到,获得积分10
1分钟前
76完成签到 ,获得积分10
1分钟前
苹果元瑶完成签到 ,获得积分10
1分钟前
能干的颦完成签到,获得积分10
1分钟前
Khan完成签到,获得积分10
2分钟前
含蓄的新柔完成签到,获得积分10
2分钟前
无心的柚子完成签到,获得积分10
2分钟前
瘦瘦的巧凡完成签到,获得积分10
2分钟前
如意嫣完成签到,获得积分10
2分钟前
Aman完成签到,获得积分10
2分钟前
wenbinvan完成签到,获得积分0
2分钟前
思源的应助被Tracy采纳,获得10
2分钟前
房天川完成签到 ,获得积分10
2分钟前
外向的念之完成签到,获得积分10
2分钟前
笑点低小霜完成签到,获得积分10
2分钟前
刻苦的刚完成签到,获得积分10
2分钟前
2分钟前
重要盼易完成签到,获得积分10
3分钟前
Tracy发布了新的文献求助10
3分钟前
典雅的醉易完成签到,获得积分10
3分钟前
冷酷紫烟完成签到,获得积分10
3分钟前
深情的晓槐完成签到,获得积分10
3分钟前
Aman完成签到,获得积分10
3分钟前
可靠秋蝶完成签到,获得积分10
3分钟前
超帅黑夜完成签到,获得积分10
3分钟前
CodeCraft的应助被无限幻枫采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370